The Conversation (0)
Madrigal Pharmaceuticals Reports 2018 First Quarter Financial Results and Reviews Key Clinical Achievements
May. 08, 2018 09:30AM PST
Pharmaceutical Investing
Madrigal Pharmaceuticals (NASDAQ:MDGL) today announced its first quarter 2018 financial results. As quoted in the press release: “The results to date from our Phase 2 clinical studies of MGL-3196 suggest, in addition to NASH, a significant potential opportunity in dyslipidemic indications, including HeFH,” stated Paul Friedman, M.D., Chief Executive Officer of Madrigal. “We look forward …
Madrigal Pharmaceuticals (NASDAQ:MDGL) today announced its first quarter 2018 financial results.
As quoted in the press release:
“The results to date from our Phase 2 clinical studies of MGL-3196 suggest, in addition to NASH, a significant potential opportunity in dyslipidemic indications, including HeFH,” stated Paul Friedman, M.D., Chief Executive Officer of Madrigal. “We look forward to exploring possible cardio-protective benefits of this mechanism as we continue our 3196 development program.”
Becky Taub, M.D., CMO and Executive VP, Research & Development of Madrigal stated, “The presentation at EASL of full 12-week, Phase 2 results of treatment of NASH patients with 3196 reinforced the consistency of improvements across a series of important biomarkers of the disease, including those related to reduction of liver fat, inflammation and fibrosis. We look forward to reviewing the final 36-week data from this study, and announcing top line results by the end of May.”
